cwf19 Antibody

What are CWF19L1 and CWF19L2 proteins and their biological significance?

CWF19L1 (CWF19-Like 1, Cell Cycle Control) and CWF19L2 (CWF19-Like 2, Cell Cycle Control) are homologous proteins involved in cell cycle regulation pathways. CWF19L1 has a predicted molecular weight of approximately 61 kDa , while CWF19L2 has a calculated molecular weight of 104 kDa and an observed molecular weight of 103 kDa in experimental conditions . These proteins are named for their homology to the CWF19 protein originally identified in Schizosaccharomyces pombe (fission yeast), suggesting evolutionary conservation of function across species. Their exact mechanisms in mammalian cell cycle control remain an active area of investigation, with current research suggesting roles in RNA processing and cell division regulation.

What antibody types are available for CWF19L1 and CWF19L2 research?

For CWF19L1 research, polyclonal antibodies targeting both N-terminal and C-terminal regions are commercially available . These antibodies are primarily rabbit-derived and available in unconjugated forms as well as with various conjugates including HRP, FITC, biotin, and fluorescent dyes for diverse experimental applications . For CWF19L2, rabbit polyclonal antibodies are available that have been validated for Western Blot, IHC, and ELISA applications . All these antibodies are developed for research use only and not for diagnostic or therapeutic applications.

Which species reactivity is confirmed for CWF19 antibodies?

CWF19L1 antibodies demonstrate confirmed reactivity with human samples, and many also show reactivity with rodent models (mouse and rat) . The N-terminal CWF19L1 antibody (ABIN2791480) has predicted reactivity with a broader range of species including cow (100%), dog (100%), guinea pig (93%), horse (93%), pig (100%), and rabbit (100%) . For CWF19L2 antibodies, human reactivity is confirmed with validation in human cell lines including HeLa, HEK-293, Jurkat, and PC-3, as well as in human kidney tissue samples .

What is the recommended sample preparation protocol for Western blotting with CWF19 antibodies?

For Western blotting using CWF19 antibodies, standard protein extraction and denaturation protocols are appropriate. Cell lysates should be prepared using RIPA buffer supplemented with protease inhibitors. For CWF19L2 detection, protein samples should be denatured at 95°C for 5 minutes in sample buffer containing SDS and a reducing agent. The recommended dilution for Western blot applications using CWF19L2 antibody ranges from 1:200 to 1:1000 . For CWF19L1 antibodies, similar protocols apply, though specific dilution recommendations may vary by manufacturer. Validated cell lines for positive controls include NIH-3T3, RT-4, U-251 MG, and human tissue lysates from plasma, liver, and tonsil .

How should I design experiments to distinguish between CWF19L1 and CWF19L2 expression patterns?

To distinguish between CWF19L1 and CWF19L2 expression patterns, a multi-method approach is recommended. Begin with Western blot analysis using specific antibodies against each protein, noting their different molecular weights (CWF19L1: ~61 kDa; CWF19L2: ~103-104 kDa) . For immunohistochemistry or immunofluorescence studies, use sequential or dual-staining approaches with appropriate controls. When designing primers for qPCR analysis, ensure they target unique regions to avoid cross-reactivity. Validation through siRNA knockdown experiments targeting each protein specifically can confirm antibody specificity. For subcellular localization studies, co-staining with organelle markers alongside CWF19L1 or CWF19L2 antibodies can reveal differential localization patterns that may reflect distinct functions.

What are the optimal conditions for immunohistochemical detection of CWF19L2 in tissue samples?

For optimal immunohistochemical detection of CWF19L2 in tissue samples, antigen retrieval with TE buffer at pH 9.0 is strongly recommended . Alternatively, citrate buffer at pH 6.0 may be used, though this may yield different staining intensities. The recommended antibody dilution range is 1:50 to 1:500, with optimal dilution requiring empirical determination for each tissue type . Human kidney tissue has been validated as a positive control for CWF19L2 immunohistochemistry. For detection, standard polymer-based or avidin-biotin complex secondary detection systems are compatible. To minimize background, include a blocking step with serum or protein blocking solution, and optimize incubation times based on tissue thickness and fixation method. Counterstaining with hematoxylin provides contextual nuclear visualization.

How can I effectively validate CWF19L1 antibody specificity in my experimental system?

To effectively validate CWF19L1 antibody specificity, implement a multi-faceted validation strategy. Begin with Western blot analysis using positive control lysates (such as NIH-3T3, RT-4, or U-251 MG cells) to confirm band size at approximately 61 kDa . Include negative controls where CWF19L1 is knocked down via siRNA or CRISPR/Cas9, which should show reduced or absent signal. Perform peptide competition assays using the immunizing peptide (e.g., synthetic peptides directed toward N-terminal or C-terminal regions) to demonstrate signal blocking. For cross-validation, compare results from antibodies targeting different epitopes (N-terminal versus C-terminal) . In immunofluorescence applications, confirm specificity through siRNA knockdown followed by staining. Additionally, recombinant expression of tagged CWF19L1 can provide a positive control for antibody validation in transfected cells.

What experimental approaches can reveal potential interaction partners of CWF19 proteins?

To identify interaction partners of CWF19 proteins, employ complementary proteomics approaches. Co-immunoprecipitation (Co-IP) using anti-CWF19L1 or anti-CWF19L2 antibodies followed by mass spectrometry analysis can identify proteins that physically interact with CWF19 proteins. Proximity-dependent biotin identification (BioID) or APEX2 proximity labeling, where CWF19 is fused to a biotin ligase, can identify both stable and transient interactors. Yeast two-hybrid screening provides an alternative approach for identifying direct binary interactions. For validation of identified interactions, reciprocal Co-IP, bimolecular fluorescence complementation (BiFC), and Förster resonance energy transfer (FRET) can confirm interactions in cellular contexts. Functional validation through co-localization studies using immunofluorescence with the identified partners and CWF19 antibodies provides additional evidence of biologically relevant interactions.

What is the recommended protocol for optimizing Western blot analysis with CWF19L1 antibodies?

For optimizing Western blot analysis with CWF19L1 antibodies, begin with standard sample preparation using RIPA buffer supplemented with protease and phosphatase inhibitors. Load 20-40 μg of total protein per lane on 10% SDS-PAGE gels, as CWF19L1 has a predicted molecular weight of 61 kDa . Transfer to PVDF membranes at 100V for 90 minutes in a wet transfer system. For blocking, use 5% non-fat dry milk in TBST for 1 hour at room temperature. Incubate with primary CWF19L1 antibody at a starting dilution of 1:250 in blocking buffer overnight at 4°C. After washing with TBST (3 × 10 minutes), incubate with appropriate HRP-conjugated secondary antibody (typically 1:5000) for 1 hour at room temperature. After washing, develop using ECL substrate and image. For optimization, test multiple antibody dilutions (1:100 to 1:1000), various blocking agents (BSA vs. milk), and different exposure times. Validated positive controls include NIH-3T3, RT-4, and U-251 MG cell lysates .

How can I determine the optimal antibody concentration for immunohistochemistry applications with CWF19L2?

To determine the optimal antibody concentration for immunohistochemistry with CWF19L2 antibody, perform a titration experiment using a known positive control tissue such as human kidney . Start with a dilution series within the recommended range of 1:50 to 1:500 . Process identical tissue sections following standardized IHC protocols including appropriate antigen retrieval with TE buffer at pH 9.0 . Compare staining intensity, specificity, and background across different concentrations. The optimal concentration should produce clear specific staining with minimal background. Additionally, include negative controls (primary antibody omitted, isotype control) to assess non-specific binding. Consider tissue-specific optimizations, as different tissues may require different antibody concentrations due to variations in target protein expression levels and tissue composition. Document the optimal conditions and include representative images in your laboratory protocols for future reference.

What controls should be included when using CWF19 antibodies in immunofluorescence studies?

When conducting immunofluorescence studies with CWF19 antibodies, include the following comprehensive controls:

Include these controls in experimental design to ensure reliable and interpretable immunofluorescence results. Document imaging parameters consistently across all samples and controls .

What are the considerations for cross-species applications of CWF19 antibodies?

When applying CWF19 antibodies across different species, several factors require careful consideration. First, evaluate sequence homology between the immunogen and the target species' protein using sequence alignment tools. The CWF19L1 N-terminal antibody shows high predicted cross-reactivity with multiple species (mouse: 86%, rat: 100%, cow: 100%, dog: 100%) , while C-terminal antibodies may show different cross-reactivity patterns. For unvalidated species, begin with Western blot analysis to confirm reactivity and specificity before proceeding to more complex applications. Optimize protocols for each species independently, as fixation requirements, antigen retrieval conditions, and antibody concentrations may differ. When possible, validate results with orthogonal methods such as RT-PCR or RNA-seq to confirm expression patterns. For immunohistochemistry applications in new species, perform comprehensive antibody titration experiments and include appropriate positive and negative controls from both the validated and target species.

Why might I observe multiple bands in Western blot analysis with CWF19L1 antibody?

Multiple bands in Western blot analysis with CWF19L1 antibody could arise from several biological and technical factors. Post-translational modifications, including phosphorylation, glycosylation, or ubiquitination, may alter protein mobility. Alternative splicing can generate isoforms of different molecular weights. Proteolytic degradation during sample preparation may produce fragments that retain the antibody epitope. Cross-reactivity with related proteins (particularly CWF19L2) could occur, especially at high antibody concentrations. To distinguish between these possibilities, use phosphatase treatment to eliminate phosphorylation-based mobility shifts. Compare results using antibodies targeting different epitopes (N-terminal vs. C-terminal) . Improve sample preparation with additional protease inhibitors and perform time-course degradation studies. Validate observed bands through targeted knockdown experiments, which should reduce or eliminate specific bands. For suspected cross-reactivity, perform peptide competition assays and gradually increase antibody dilution to improve specificity.

How should I interpret contradictory results between Western blot and immunohistochemistry when using CWF19 antibodies?

When encountering contradictory results between Western blot and immunohistochemistry with CWF19 antibodies, consider fundamental differences between these techniques. Western blot detects denatured proteins, while IHC detects proteins in their native conformation and cellular context. Begin troubleshooting by verifying antibody compatibility with both applications—some antibodies perform well in one application but not another. For CWF19L2 antibody, note that while the recommended dilution for Western blot is 1:200-1:1000, IHC applications require 1:50-1:500, suggesting different sensitivity requirements .

Evaluate epitope accessibility issues in IHC by testing alternative antigen retrieval methods (TE buffer pH 9.0 vs. citrate buffer pH 6.0) . For Western blot, try different extraction buffers to ensure complete protein solubilization. Consider cross-validation with alternative antibodies targeting different epitopes of the same protein. Cell-type specific or subcellular localization differences may appear contradictory between whole-tissue lysates (WB) and intact tissue architecture (IHC). Finally, quantify and document these differences systematically rather than dismissing them as technical failures, as they may reflect important biological phenomena worthy of further investigation.

What strategies can resolve weak or absent signals when using CWF19 antibodies?

To resolve weak or absent signals when using CWF19 antibodies, implement a systematic optimization strategy. First, verify target protein expression in your experimental system through RT-PCR or RNA-seq data before antibody troubleshooting. For Western blot applications, increase protein loading (40-60 μg), reduce antibody dilution (1:100 for CWF19L2 or 1:100 for CWF19L1 ), and extend primary antibody incubation to overnight at 4°C. Use enhanced chemiluminescence (ECL) substrates with higher sensitivity and optimize exposure times. For immunohistochemistry, test alternative antigen retrieval methods—CWF19L2 detection recommends TE buffer at pH 9.0, with citrate buffer at pH 6.0 as an alternative . Extend primary antibody incubation time to 24-48 hours at 4°C and employ signal amplification systems such as tyramide signal amplification. For all applications, use positive control samples with confirmed target expression (HeLa, HEK-293, Jurkat, or PC-3 cells for CWF19L2 ; NIH-3T3, RT-4, or U-251 MG for CWF19L1 ). Fresh antibody aliquots may be necessary if repeated freeze-thaw cycles have compromised antibody activity.

How can I quantitatively analyze CWF19 protein expression levels across different experimental conditions?

For quantitative analysis of CWF19 protein expression across different experimental conditions, employ these methodological approaches:

• Western Blot Densitometry: Normalize CWF19 band intensity to loading controls (β-actin, GAPDH). Use technical triplicates and biological replicates (n≥3) for statistical validity. Ensure signal falls within the linear range of detection by performing dilution series experiments.

• Quantitative Immunofluorescence: Measure fluorescence intensity of CWF19 staining relative to DAPI or other cellular markers. Analyze multiple fields (>10) and cells (>100) per condition using consistent acquisition parameters.

• Flow Cytometry: For intracellular CWF19 detection, standardize with calibration beads to convert fluorescence intensity to molecules of equivalent soluble fluorochrome (MESF).

• Multiplexed Approaches: Combine CWF19 detection with other proteins of interest using multiplexed Western blotting or immunostaining to correlate expression patterns.

For all methods, include appropriate statistical analysis (ANOVA with post-hoc tests for multiple comparisons) and visualization (box plots or violin plots rather than bar graphs to show data distribution). Report both fold-changes and absolute values when possible, with clear descriptions of normalization methods and reference standards used .

How can CWF19 antibodies be utilized in studying protein-protein interactions and complex formation?

CWF19 antibodies can be powerful tools for studying protein-protein interactions and complex formation through multiple advanced methodological approaches. For co-immunoprecipitation (Co-IP) studies, use anti-CWF19L1 or CWF19L2 antibodies to pull down the target protein under native conditions, followed by Western blot analysis to detect interacting partners. Optimize buffer conditions (salt concentration, detergent type) to preserve interactions while minimizing non-specific binding. Proximity ligation assay (PLA) offers an alternative approach, where antibodies against CWF19 and a suspected interaction partner are used together with oligonucleotide-conjugated secondary antibodies to generate fluorescent signals only when proteins are within 40 nm of each other. For chromatography-based approaches, antibodies can be used for immunoaffinity purification followed by size-exclusion chromatography to isolate intact complexes. Mass spectrometry analysis of isolated complexes can identify both known and novel interaction partners. For validation of specific interactions, reciprocal Co-IPs and knockdown studies should be performed to confirm specificity and biological relevance of identified interactions.

What are the considerations for using CWF19 antibodies in chromatin immunoprecipitation (ChIP) experiments?

When considering CWF19 antibodies for chromatin immunoprecipitation (ChIP) experiments, several critical factors must be addressed. First, evaluate whether the CWF19 protein is expected to interact with DNA directly or as part of a larger complex, as this will influence experimental design. While current commercial CWF19L1 and CWF19L2 antibodies have not been specifically validated for ChIP applications , they may be suitable following rigorous validation. Begin validation with small-scale ChIP experiments using positive control cells with known high expression (HEK-293 or HeLa cells for CWF19L2 ). Optimize crosslinking conditions (formaldehyde concentration and time) and sonication parameters to achieve consistent chromatin fragmentation to 200-500 bp. Use ChIP-grade antibodies or validate existing antibodies through preliminary ChIP-qPCR targeting genomic regions associated with RNA processing or cell cycle regulation, where CWF19 proteins might function. Include appropriate controls: input chromatin, IgG negative control, and a positive control antibody against a known DNA-binding protein. For ChIP-seq experiments, ensure sufficient sequencing depth (>20 million reads) and perform replicate experiments to identify reproducible binding sites.

How can I integrate CWF19 protein expression data with transcriptomics and proteomics datasets?

Integrating CWF19 protein expression data with transcriptomics and proteomics datasets requires a multi-layered bioinformatics approach. Begin by establishing quantitative CWF19 protein expression across conditions using antibody-based techniques (Western blot, immunohistochemistry, or ELISA) . Normalize protein expression data appropriately before integration with other datasets. For correlation with transcriptomics, align CWF19L1/L2 protein levels with corresponding mRNA expression using Pearson or Spearman correlation coefficients to assess post-transcriptional regulation. In proteomics datasets, identify co-regulated protein networks through weighted gene correlation network analysis (WGCNA) or similar algorithms to place CWF19 proteins within functional modules. Pathway enrichment analysis of these modules can reveal biological processes associated with CWF19 function. To identify potential regulatory relationships, perform causal network analysis using methods such as Bayesian network inference. Visualization tools like Cytoscape with multi-omics plugins can generate integrated network visualizations. For validation of key findings, design targeted experiments using CWF19 antibodies in conjunction with other methods to confirm predicted relationships or functions identified through computational integration.

What are the latest developments in using CWF19 antibodies for super-resolution microscopy?

Super-resolution microscopy applications using CWF19 antibodies represent an emerging frontier that overcomes diffraction limits to reveal nanoscale protein localization and interactions. While these applications are still developing for CWF19 proteins specifically, researchers can adapt existing CWF19L1 and CWF19L2 antibodies for super-resolution techniques. For Structured Illumination Microscopy (SIM), standard immunofluorescence protocols can be employed with CWF19 antibodies at optimized dilutions, offering approximately 100 nm resolution, sufficient for examining CWF19 distribution relative to nuclear or cytoplasmic structures. For higher resolution techniques like Stimulated Emission Depletion (STED) microscopy, directly conjugated CWF19 antibodies or high-quality secondary antibodies with appropriate fluorophores (ATTO or Abberior dyes) should be used. Single-molecule localization microscopy (STORM/PALM) requires photoswitchable fluorophore-conjugated antibodies and careful sample preparation to minimize background. For all super-resolution applications, sample preparation quality is critical—optimize fixation methods to preserve cellular ultrastructure while maintaining antibody accessibility to CWF19 epitopes. Multi-color super-resolution imaging can reveal precise spatial relationships between CWF19 proteins and potential interaction partners or cellular structures at nanometer resolution.

What are the emerging research areas where CWF19 antibodies will be increasingly valuable?

CWF19 antibodies are becoming increasingly valuable in several emerging research areas. In RNA processing and splicing regulation studies, these antibodies can help elucidate the role of CWF19 proteins in spliceosome assembly and function. Cell cycle regulation research benefits from CWF19 antibodies to investigate their potential roles in checkpoint control mechanisms. In cancer biology, evaluating CWF19 expression patterns across tumor types may reveal new diagnostic or prognostic biomarkers. Neurodegenerative disease research is exploring RNA processing factors like CWF19 for potential contributions to pathogenesis. Developmental biology studies can utilize these antibodies to track expression patterns during embryogenesis and tissue differentiation. Single-cell protein analysis technologies will increasingly incorporate CWF19 antibodies for higher-resolution cellular heterogeneity studies. Finally, therapeutic target validation efforts may employ these antibodies to evaluate the potential of CWF19 proteins as novel intervention points. As antibody technologies advance, enhanced versions with improved specificity, sensitivity, and conjugation options will further expand the range of applications in these emerging fields .